PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.
Morgan, Robert D
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer. [electronic resource] - Cancer chemotherapy and pharmacology 04 2018 - 647-658 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
1432-0843
10.1007/s00280-018-3532-9 doi
Cystadenocarcinoma, Serous--drug therapy
Drug Resistance, Neoplasm--drug effects
Female
Humans
Ovarian Neoplasms--drug therapy
Platinum--administration & dosage
Poly(ADP-ribose) Polymerase Inhibitors--therapeutic use
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer. [electronic resource] - Cancer chemotherapy and pharmacology 04 2018 - 647-658 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
1432-0843
10.1007/s00280-018-3532-9 doi
Cystadenocarcinoma, Serous--drug therapy
Drug Resistance, Neoplasm--drug effects
Female
Humans
Ovarian Neoplasms--drug therapy
Platinum--administration & dosage
Poly(ADP-ribose) Polymerase Inhibitors--therapeutic use